Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma-Reference-Cited by-同舟云学术

Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma

Published:2023-01-01 Issue:1 Volume:5 Page:
ISSN:2632-2498
Container-title:Neuro-Oncology Advances
language:en
Short-container-title:

Author:

Bernstock Joshua D¹²³^ORCID,Blitz Sarah E⁴,Hoffman Samantha E⁴⁵,Gerstl Jakob V E¹,Chiocca E Antonio¹,Friedman Gregory K⁶⁷

Affiliation:

1. Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School , Boston, Massachusetts , USA

2. Department of Neurosurgery, Boston Children’s Hospital, Harvard Medical School , Boston, Massachusetts , USA

3. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology , Cambridge, Massachusetts , USA

4. Harvard Medical School , Boston, Massachusetts , USA

5. Harvard-MIT MD-PhD Program, Harvard Medical School , Boston, Massachusetts , USA

6. Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham , Birmingham, Alabama , USA

7. Comprehensive Cancer Center, University of Alabama at Birmingham , Birmingham, Alabama , USA

Abstract

Abstract Adult and pediatric high-grade gliomas (HGGs) are aggressive cancers of the central nervous system that confer dismal clinical prognoses. Standard radiation and chemotherapy have demonstrated only limited efficacy in HGGs, motivating the accelerated investigation of novel modalities such as oncolytic virus (OV) therapies. OV centered therapies work through a mixed mechanism centered on oncolysis and the stimulation of an antitumor immune response. Three recent clinical trials utilizing herpes simplex virus-1 and adenovirus-based oncolytic virotherapy demonstrated not only the safety and efficacy of OVs but also novel dosing strategies that augment OV response potential. Considering these recent trials, herein we present a roadmap for future clinical trials of oncolytic immunovirotherapy in both adult and pediatric HGG, as well as persistent roadblocks related to the assessment of OV efficacy within and between trials.

Funder

Kiki Leptomeningeal Disease Research Fund

Publisher

Oxford University Press (OUP)

Subject

Surgery,Oncology,Neurology (clinical)

Link

https://academic.oup.com/noa/advance-article-pdf/doi/10.1093/noajnl/vdad081/50839054/vdad081.pdf

Reference50 articles.

1. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017;Ostrom;Neuro-Oncology,2020

2. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med.,2005

3. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis;Marenco-Hillembrand;J Neurooncol.,2020